The forward-looking information contained herein, including, without limitation, statements related to Mikra reaching additional customers in 2024, are made as of the date of this news release and are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, the effectiveness and benefits of CELLF 2.0 are as anticipated, customer interest in Mikras products including CELLF 2.0 and resulting sales will be as anticipated, its expectation that the nutraceutical market will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, expectations that CELLF, CELLF 2.0, RESCUE, SERENITY, PROTECT and other new nutraceutical products to be developed by Mikra will gain market acceptance along with the expansion of the market for nutraceutical products, as well as other considerations that are believed to be appropriate in the circumstances

Phase 2 NEJM 2023: 24.2% at 48 weeks
The reoccurrence of cataracts is, unfortunately, quite common
Jia et al
Many people choose B12 injections for general wellbeing and energy support even without a clinical deficiency
doi: 10.4049/jimmunol.1800565 14 BaierDMllerTMohrTWindbergerU